We investigated the effects of cisplatin (0–15.23 μg/mL), C. nutans (0–50 μg/mL), and a combination of cisplatin (3.05 μg/mL) and C. nutans (0–50 μg/mL), on cell viability, proliferation, apoptosis, invasion, mRNA expression in cancer stem cells (CD49f, KLF4), and differentiation markers (TUBA1A, KRT18) in TNBC cells. Here, TUBA1A is linked to cancer.